Head and Neck Neuroendocrine Carcinoma

subtype

Identifier: CI-CAN-00000961
Entity page: /cancer/head-and-neck-neuroendocrine-carcinoma ↗
Edges: 144

Neighbours: 15 drugs10 trials
Drawn: 25 of 25 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Head and Neck Neuroendocrine Carcinoma approved for …APPROVED_FORderived6 of 6
← approved for	Selpercatinibsmall molecule FDA (US) · approved · 2024-04-10 · Adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as de…	—	approved	Thyroid Gland Medullary Carcinoma	1	Regulatory	openfda	graph →
← approved for

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

RET Mutation SelpercatinibFDA US 2020-05-085 active / 6 trials
Curatedlevel Asensitivity· support 3civicObservedcohort frequency not yet available for RET in this cancerRegulatoryapproved for Thyroid Gland Medullary Carcinoma (5 approval records)context: Thyroid Gland Medullary Carcinoma
RET M918T SelpercatinibFDA US 2020-05-085 active / 6 trials
Curatedlevel Asensitivity· support 2civicObservedcohort frequency not yet available for RET in this cancerRegulatoryapproved for Thyroid Gland Medullary Carcinoma (5 approval records)context: Thyroid Gland Medullary Carcinoma
RET E632_L633del SelpercatinibFDA US 2020-05-085 active / 6 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for RET in this cancerRegulatoryapproved for Thyroid Gland Medullary Carcinoma (5 approval records)context: Thyroid Gland Medullary Carcinoma
RET M918T CabozantinibFDA US 2012-11-294 active / 9 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for RET in this cancerRegulatoryapproved for Thyroid Gland Medullary Carcinoma (2 approval records)context: Thyroid Gland Medullary Carcinoma
RET M918T Sorafenib0 active / 3 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for RET in this cancerno approval record in this cancercontext: Thyroid Gland Medullary Carcinoma
RET V804M SelpercatinibFDA US 2020-05-085 active / 6 trials
Curatedlevel Csensitivity· support 2civicObservedcohort frequency not yet available for RET in this cancerRegulatoryapproved for Thyroid Gland Medullary Carcinoma (5 approval records)context: Thyroid Gland Medullary Carcinoma
RET M918T JAK2 Inhibitor AZD14800 active / 0 trials
Curatedlevel Dsensitivity· support 1civicObservedcohort frequency not yet available for RET in this cancerno approval record in this cancercontext: Thyroid Gland Medullary Carcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Head and Neck Neuroendocrine Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 30show all (up to 200)
→ investigated in trials for	Cabozantinibsmall molecule 9 trials (4 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Neuroendocrine Carcinoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Vandetanibsmall molecule 9 trials (1 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Neuroendocrine Carcinoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Selpercatinibsmall molecule 6 trials (5 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Neuroendocrine Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Pralsetinibsmall molecule 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Neuroendocrine Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Sorafenibsmall molecule 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Neuroendocrine Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Everolimussmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Neuroendocrine Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenvatinibsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Neuroendocrine Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Neuroendocrine Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Sunitinibsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Neuroendocrine Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Bortezomibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Cixutumumabmonoclonal antibody 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Dexamethasonesmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →

Head and Neck Neuroendocrine Carcinoma studied in …STUDIED_INderived10 of 108show all (up to 200)
→ studied in	NCT06479811Phase 1 · recruiting [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers · condition mapped ONTOLOGY_EXACT · 108 trials mapped (40 active)	—	—	Sinonasal Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04216732recruiting Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management · condition mapped CURATED_BROADER · 108 trials mapped (40 active)	—	—	Thyroid Gland Medullary Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07142005recruiting Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer · condition mapped ALIAS · 108 trials mapped (40 active)	—	—	Thyroid Gland Medullary Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02293954NA · active not recruiting Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer · condition mapped ONTOLOGY_EXACT · 108 trials mapped (40 active)	—	—	Thyroid Gland Medullary Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01660984active not recruiting Natural History Study of Children and Adults With Medullary Thyroid Cancer · condition mapped ALIAS · 108 trials mapped (40 active)	—	—	Thyroid Gland Medullary Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04522570NA · completed Thermal Ablation of Cervical Metastases From Thyroid Carcinoma · condition mapped ALIAS · 108 trials mapped (40 active)	—	—	Thyroid Gland Medullary Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06814496Phase 1/Phase 2 · recruiting Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors · condition mapped ALIAS · 108 trials mapped (40 active)	—	—	Thyroid Gland Medullary Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07006727Phase 1 · recruiting Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors · condition mapped ALIAS · 108 trials mapped (40 active)	—	—	Thyroid Gland Medullary Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04467021NA · active not recruiting Cancer and Blood Pressure Management, CARISMA Study · condition mapped CURATED_BROADER · 108 trials mapped (40 active)	—	—	Thyroid Gland Medullary Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07812779not yet recruiting Thyroid Health Outcomes Registry for Surgery · condition mapped ALIAS · 108 trials mapped (40 active)	—	—	Thyroid Gland Medullary Carcinoma	1	Observed	clinicaltrials	graph →